Possible roles of L-phosphoserine in the pathogenesis of Alzheimer's disease - PubMed (original) (raw)
Review
Possible roles of L-phosphoserine in the pathogenesis of Alzheimer's disease
W E Klunk et al. Mol Chem Neuropathol. 1991 Aug.
Abstract
L-Phosphoserine is a membrane metabolite that is elevated in Alzheimer's disease brain. This compound has close structural similarity to L-glutamate. Electrophysiological studies indicate that L-phosphoserine has an acute inhibitory effect, but a delayed excitatory action. A hypothesis is developed based on pharmacological and electrophysiological studies that suggest that the inhibition may be mediated through presynaptic inhibition of L-glutamate release or perhaps antagonism of postsynaptic kainic acid receptors. The mechanism of the delayed excitation may lie in the tendency of L-phosphoserine to mimic the action of L-2-amino-4-phosphonobutyric acid, a blocker of chloride- and calcium-sensitive L-glutamate transport. L-Phosphoserine has also been found to be a competitive antagonist at the N-methyl-D-aspartate recognition site and an antagonist of metabotropic receptor-mediated hydrolysis of inositol phospholipids. Because of these actions, there are several potentially important implications for the elevation of L-phosphoserine in Alzheimer's disease, including production memory impairment through presynaptic inhibition of L-glutamate release or blockade of postsynaptic N-methyl-D-aspartate receptors and/or blockade of certain L-glutamate transport sites resulting in increased L-glutamate levels in the synaptic cleft.
Similar articles
- L-phosphoserine, a metabolite elevated in Alzheimer's disease, interacts with specific L-glutamate receptor subtypes.
Klunk WE, McClure RJ, Pettegrew JW. Klunk WE, et al. J Neurochem. 1991 Jun;56(6):1997-2003. doi: 10.1111/j.1471-4159.1991.tb03458.x. J Neurochem. 1991. PMID: 1673996 - Activation of presynaptic group III metabotropic receptors enhances glutamate release in rat entorhinal cortex.
Evans DI, Jones RS, Woodhall G. Evans DI, et al. J Neurophysiol. 2000 May;83(5):2519-25. doi: 10.1152/jn.2000.83.5.2519. J Neurophysiol. 2000. PMID: 10805653 - d-glutamate and Gut Microbiota in Alzheimer's Disease.
Chang CH, Lin CH, Lane HY. Chang CH, et al. Int J Mol Sci. 2020 Apr 11;21(8):2676. doi: 10.3390/ijms21082676. Int J Mol Sci. 2020. PMID: 32290475 Free PMC article. Review. - Glutamate-glutamine cycling in Alzheimer's disease.
Walton HS, Dodd PR. Walton HS, et al. Neurochem Int. 2007 Jun;50(7-8):1052-66. doi: 10.1016/j.neuint.2006.10.007. Epub 2006 Dec 1. Neurochem Int. 2007. PMID: 17141374 Review.
Cited by
- Progress toward advanced understanding of metabotropic glutamate receptors: structure, signaling and therapeutic indications.
Yin S, Niswender CM. Yin S, et al. Cell Signal. 2014 Oct;26(10):2284-97. doi: 10.1016/j.cellsig.2014.04.022. Epub 2014 May 2. Cell Signal. 2014. PMID: 24793301 Free PMC article. Review. - Selectivity and evolutionary divergence of metabotropic glutamate receptors for endogenous ligands and G proteins coupled to phospholipase C or TRP channels.
Kang HJ, Menlove K, Ma J, Wilkins A, Lichtarge O, Wensel TG. Kang HJ, et al. J Biol Chem. 2014 Oct 24;289(43):29961-74. doi: 10.1074/jbc.M114.574483. Epub 2014 Sep 5. J Biol Chem. 2014. PMID: 25193666 Free PMC article. - Widespread activation of calcium-activated neutral proteinase (calpain) in the brain in Alzheimer disease: a potential molecular basis for neuronal degeneration.
Saito K, Elce JS, Hamos JE, Nixon RA. Saito K, et al. Proc Natl Acad Sci U S A. 1993 Apr 1;90(7):2628-32. doi: 10.1073/pnas.90.7.2628. Proc Natl Acad Sci U S A. 1993. PMID: 8464868 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical